universal allogeneic anti-CD19/BCMA CAR T-cells

BIOLOGICAL2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Changzhou No.2 People's Hospital

Conditions

ANCA-Associated VasculitisAutoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsIgG4-RDInflammatory MyopathyMyasthenia GravisSystemic Lupus ErythematosusSystemic Sclerosis

Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

RecruitingNCT06733610

Institute of Hematology & Blood Diseases Hospital, ChinaAutoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells, Universal Allogeneic CAR T-cells

Start: 2024-12-05End: 2026-12-05Target: 15Updated: 2024-12-13

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Not yet recruitingNCT06978738

Changzhou No.2 People's HospitalANCA-Associated Vasculitis, Autoimmune Hemolytic Anemia, IgG4-RD +4

Start: 2025-05-31End: 2028-11-30Target: 18Updated: 2025-05-18

Related Papers

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

Blood2025-11-03